{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:02:14Z","timestamp":1789740134136,"version":"4.0.1"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"unspecified","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIHR Oxford Health Biomedical Research Centre","award":["NIHR203316"],"award-info":[{"award-number":["NIHR203316"]}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Holmusk Technologies, Inc","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100000282","name":"Sir Jules Thorn Charitable Trust","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100000282","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2026,7,27]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cognitive deficits across psychiatric disorders are common and difficult to treat. Semaglutide, a GLP-1 receptor agonist, shows potential cognitive benefits in diabetes and obesity, but effects in psychiatric populations remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine whether initiation of semaglutide is associated with fewer cognitive signs\/symptoms over 12 months among adults with psychiatric disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective cohort study using de-identified multicentre US electronic health records (EHRs) in NeuroBlu Data spanning 1999\u20132024. We included adults with any International Classification of Diseases (ICD)-9\/-10 psychiatric diagnosis with at least one semistructured, clinician-rated routine cognitive assessment in the 12 months before and at least one in the 12 months after initiating an antidiabetic drug. Semaglutide initiation was compared against four comparator strategies including sitagliptin, empagliflozin, glipizide or no antidiabetic treatment. Primary outcome was a 0\u2013100\u2009composite cognitive score (0, no signs\/symptoms recorded; 100, signs\/symptoms present across all domains) derived from semistructured, clinician-rated routine cognitive assessments across memory, attention, orientation and other cognitive functions, with a 12-month follow-up after antidiabetic drug initiation. We estimated mean ratios (MR) and 95% CIs between comparisons with the parametric g-formula, adjusting for baseline cognitive score and prespecified covariates. Additional analyses were conducted for individual cognitive domains and also grouped by major depression, psychosis and bipolar disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Among 13\u2009007 individuals (mean (SD) age, 62.0 (13.4) years; 6300 (48.4%) female), 1261 initiated semaglutide. Across psychiatric disorders, mean cognitive signs\/symptoms scores over 12 months were lower with semaglutide (11.14) than with no treatment (14.91; MR, 0.75 (0.65\u20130.85); Bonferroni-corrected p=0.00002), glipizide (13.46; MR 0.83 (0.70\u20130.93); p=0.041) or empagliflozin (13.69; MR, 0.81 (0.69\u20130.94); p=0.016) and lower but not significantly different from sitagliptin (12.52; MR, 0.89 (0.77\u20131.02); p=0.50). Associations were stronger for memory and broader cognitive functions. Similar effect sizes were seen across disorders but were only consistently significant in major depression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this EHR-based cohort of adults with psychiatric disorders, semaglutide initiation was associated with lower clinician-recorded cognitive signs\/symptoms than several comparators over 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical implications<\/jats:title>\n                    <jats:p>Randomised clinical trials are needed to confirm causality and clinical utility of semaglutide to reduce cognitive signs\/symptoms in psychiatric disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2026-302828","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:15:17Z","timestamp":1787231717000},"page":"e302828","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Cognitive signs and symptoms in people with a psychiatric diagnosis on semaglutide: a retrospective cohort study of 13\u2009007\u2009patients in the USA"],"prefix":"10.1136","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5984-8696","authenticated-orcid":false,"given":"Riccardo","family":"De Giorgi","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Oxford, England, UK"},{"name":"Oxford Health NHS Foundation Trust, Oxford, England, UK"},{"name":"Department of Experimental Medicine, University of Salento, Lecce, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Lipunova","sequence":"additional","affiliation":[{"name":"Holmusk Technologies Inc. UK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elgan","family":"Mathias","sequence":"additional","affiliation":[{"name":"Holmusk Technologies Inc. UK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Oxford, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-952X","authenticated-orcid":false,"given":"Maxime","family":"Taquet","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Oxford, England, UK"},{"name":"Oxford Health NHS Foundation Trust, Oxford, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2026091806111395000_29.1.e302828.1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41386-023-01729-7","article-title":"Transdiagnostic subgroups of cognitive impairment in early affective and psychotic illness","volume":"49","author":"Wenzel","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"2026091806111395000_29.1.e302828.2","doi-asserted-by":"crossref","first-page":"1046692","DOI":"10.3389\/fncel.2022.1046692","article-title":"Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention","volume":"16","author":"Wang","year":"2022","journal-title":"Front Cell Neurosci"},{"key":"2026091806111395000_29.1.e302828.3","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.24r15316","article-title":"The Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia: A Targeted Literature Review With a Focus on Outcomes Relevant to Health Care Decision-Makers in the United States","volume":"85","author":"Correll","year":"2024","journal-title":"J Clin Psychiatry"},{"key":"2026091806111395000_29.1.e302828.4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jpsychires.2021.05.003","article-title":"Cognitive impairment and consumption of mental healthcare resources in outpatients with bipolar disorder","volume":"138","author":"Ribera","year":"2021","journal-title":"J Psychiatr Res"},{"key":"2026091806111395000_29.1.e302828.5","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-022-02249-6","article-title":"Pharmacological targeting of cognitive impairment in depression: recent developments and challenges in human clinical research","volume":"12","author":"Colwell","year":"2022","journal-title":"Transl Psychiatry"},{"key":"2026091806111395000_29.1.e302828.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-01949-9"},{"key":"2026091806111395000_29.1.e302828.7","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3628"},{"key":"2026091806111395000_29.1.e302828.8","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026091806111395000_29.1.e302828.9","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-335593"},{"key":"2026091806111395000_29.1.e302828.10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102726","article-title":"12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study","volume":"74","author":"De Giorgi","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026091806111395000_29.1.e302828.11","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14313"},{"key":"2026091806111395000_29.1.e302828.12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-025-04106-7","article-title":"Liraglutide in mild to moderate Alzheimer\u2019s disease: a phase 2b clinical trial","volume":"32","author":"Edison","year":"2026","journal-title":"Nat Med"},{"key":"2026091806111395000_29.1.e302828.13","unstructured":"Nordisk N . Evoke phase 3 trials did not demonstrate a statistically significant reduction in alzheimer\u2019s disease progression. n.d. Available: https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=916462"},{"key":"2026091806111395000_29.1.e302828.14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"2026091806111395000_29.1.e302828.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30173-3"},{"key":"2026091806111395000_29.1.e302828.16","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230922"},{"key":"2026091806111395000_29.1.e302828.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057227","article-title":"NeuroBlu, an electronic health record (EHR) trusted research environment (TRE) to support mental healthcare analytics with real-world data","volume":"12","author":"Patel","year":"2022","journal-title":"BMJ Open"},{"key":"2026091806111395000_29.1.e302828.18","doi-asserted-by":"crossref","DOI":"10.1016\/j.patter.2020.100008","article-title":"gfoRmula: An R Package for Estimating the Effects of Sustained Treatment Strategies via the Parametric g-formula","volume":"1","author":"McGrath","year":"2020","journal-title":"Patterns (N Y)"},{"key":"2026091806111395000_29.1.e302828.19","doi-asserted-by":"publisher","DOI":"10.1016\/0270-0255(86)90088-6"},{"key":"2026091806111395000_29.1.e302828.20","doi-asserted-by":"crossref","first-page":"100916","DOI":"10.1016\/j.medj.2025.100916","article-title":"Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial","volume":"7","author":"Badulescu","year":"2026","journal-title":"Med"},{"key":"2026091806111395000_29.1.e302828.21","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.180.4.313"},{"key":"2026091806111395000_29.1.e302828.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12300-9"},{"key":"2026091806111395000_29.1.e302828.23","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials","volume":"11","author":"Gilbert","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026091806111395000_29.1.e302828.24","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s44220-025-00390-x","article-title":"An analysis on the role of glucagon-like peptide 1 receptor agonists in cognitive and mental health disorders","volume":"3","author":"De Giorgi","year":"2025","journal-title":"Nat Ment Health"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2026-302828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:11:53Z","timestamp":1789737113000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2026-302828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,8,20]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bmjment-2026-302828"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2026-302828","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}